Behavioral Science: Enhancing Our Approach to the Development of Effective Additional Risk Minimization Strategies

Joanne Treacy, Elaine H. Morrato, Robert Horne, Michael S. Wolf, Ameet Bakhai, Marie-Claire Wilson, Mark Lightowler, Sibel Guerler and Jeremy Jokinen ()
Additional contact information
Joanne Treacy: Bristol Myers Squibb
Elaine H. Morrato: Loyola University Chicago
Robert Horne: Spoonful of Sugar Ltd, University College London Business Company
Michael S. Wolf: Northwestern University
Ameet Bakhai: The Royal Free and University College Medical School
Marie-Claire Wilson: Axian Consulting, Ltd.
Mark Lightowler: King’s College London
Sibel Guerler: Bristol Myers Squibb
Jeremy Jokinen: Bristol Myers Squibb

Drug Safety, 2024, vol. 47, issue 8, No 2, 733-743

Abstract: Abstract Additional risk minimization strategies may be required to assure a positive benefit–risk balance for some therapeutic products associated with serious adverse drug reactions/risks of use, without which these products may be otherwise unavailable to patients. The goals of risk minimization strategies are often fundamentally to influence the behavior of healthcare professionals (HCPs) and/or patients and can include appropriate patient selection, provision of education and counselling, appropriate medication use, adverse drug reaction monitoring, and adoption of other elements to assure safe use, such as pregnancy prevention. Current approaches to additional risk minimization strategy development rely heavily on information provision, without full consideration of the contextual factors and multi-level influences on patient and HCP behaviors that impact adoption and long-term adherence to these interventions. Application of evidence-based behavioral science methods are urgently needed to improve the quality and effectiveness of these strategies. Evidence from the fields of adherence, health promotion, and drug utilization research underscores the value and necessity for using established behavioral science frameworks and methods if we are to achieve clinical safety goals for patients. The current paper aims to enhance additional risk minimization strategy development and effectiveness by considering how a behavioral science approach can be applied, drawing from evidence in understanding of engagement with pharmaceutical medicines as well as wider public health interventions for patients and HCPs.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-024-01420-w Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:47:y:2024:i:8:d:10.1007_s40264-024-01420-w

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-024-01420-w

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().